NAb template draft

[monicagerber]

Thanks for reviewing the NAb template draft.

To create this draft, I reviewed:

• Dubois846 NAb report
• Caskey820 NAb report
• McElrath 708 and 749 NAb reports
• Gallo 477 NAb report
• HVTN reports package NAb memo template
• VISC-Assay-Methods repo

Some notes:

• I used "net ID50 titer" (subscript does not work in Github comments!) consistently to refer to the statistical endpoint. This hasn't been consistent in past reports. We've used a combination of SLV-subtracted ID50 titer, ID50 titers, NAb titers, etc. to refer to the subtracted endpoint.
• There's a note to check for SLV-subtraction in the lab study plan.
• HVTN uses "IC50".
• I moved the MB description to the graphical analysis and adopted the language from HTVN reports which I thought was easier to understand.

Can you please complete this review by COB 1/20? Let me know if you need additional time. I may schedule a working meeting for us to review edits like we did with BAMA.

Thank you!

[monicagerber]

Hi @mayerbry, we talked about looking at recent publications so we can decide on the best name for the response magnitude. If you could point us to some links or make a suggestion, that'd be helpful. Thanks in advance!

[monicagerber]

I found two recent examples of clinical work with nab results and they use "ID50 Titer" or similar so I think we should stick with that. For pre-clinical work (and rare clinical work) there are background/control titers like MLV. This is not the standard case, but I think there should be a comment reminder that the titer calculation should be verified and explicitly defined if there is subtraction. The correct notation (ex, net ID50 titer or MLV-subtracted titer) for plots can be established per conversation with lead stat/lab under those circumstances.

HVTN405 Gallo477

Thanks, Bryan. This is helpful. I changed the methods to "ID~50~ titer" and added a note about MLV-subtracted titers to the top.

[monicagerber]

Hi @asatofh, please let me know if you approve these changes. Once you approve, I can merge this PR.